Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Colorado Biotechnology Associates (CBA) was a specialty biotechnology company that specialized in the development and manufacture of functionalized polymeric resins used in solid-phase peptide synthesis (SPPS). Founded in 1981 by Dr. Rodger Raubach and based in Casper, Wyoming, the company produced a wide range of specialty resins, including Knorr-MBHA, Wang, and aminoethyl resins, which are essential for combinatorial chemistry and the production of peptide-based therapeutics. CBA's technology enabled the attachment of specific terminal amino acids to resins used as solid-state supports, facilitating the scale-up of peptide production. In January 2006, the company's technology assets and customer lists were acquired by Synthetech, Inc., a provider of peptide building blocks. This acquisition allowed Synthetech to expand its offerings into the specialty resin market for GMP peptide manufacturing.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Colorado Biotechnology Associates.